Ioanna Voulgaridi

Dr. Ioanna Voulgaridi

University of Thessaly, Larissa, Greece
orcid
Faculty of Medicine, University of Thessaly, 41500 Larissa, ...

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
KDKaterina Dadouli
Katerina Dadouli
MJMichel Janho
Michel Janho
AHApostolia Hatziefthimiou
Apostolia Hatziefthimiou
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
KPKonstantina Piaha
Konstantina Piaha
Christos HadjichristodoulouChristos Hadjichristodoulou
Christos Hadjichristodoulou
The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammatory (SII) index, which provide a simple, rapid, inexpensive method to measure the level of inflammation, have been examined as potential inflammatory biomarkers of bipolar disorder (BD) in several studies. We conducted a case-control study recruiting 180 BD patients and 407 healthy controls. BD patients who met the inclusion criteria and were hospitalized due to BD at the psychiatry clinic of the University General Hospital of Larisa, Greece, until September 2021 were included in the study. Among them, 111 patients experienced a manic episode and 69 patients experienced a depressive episode. Data including a complete blood count were retrieved from their first admission to the hospital. Bipolar patients had a higher NLR, MLR and SII index compared to healthy controls when they were experiencing a manic episode (p < 0.001) and a depressive episode (p < 0.001). MLR was increased with large effect size only in patients expressing manic episodes. Neutrophils and NLR had the highest area under the curve with a cutoff of 4.38 and 2.15 in the ROC curve, respectively. Gender-related differences were mainly observed in the SII index, with males who were expressing manic episodes and females expressing depressive episodes having an increased index compared to healthy controls. The NLR, MLR and SII index were significantly higher in patients with BD than in healthy controls, which implies a higher grade of inflammation in BD patients.

1 March 2019 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
CCC. Chatedaki
C. Chatedaki
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
MKM. Kachrimanidou
M. Kachrimanidou
JHJaroslav Hrabák
Jaroslav Hrabák
Constantinos PapagiannitsisConstantinos Papagiannitsis
Constantinos Papagiannitsis
Efthymia PetinakiEfthymia Petinaki
Efthymia Petinaki

1 October 2018 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
EMErgina Malli
Ergina Malli
ZFZoi Florou
Zoi Florou
KTKaterina Tsilipounidaki
Katerina Tsilipounidaki
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
ASAggelos Stefos
Aggelos Stefos
Efthymia PetinakiEfthymia Petinaki
Efthymia Petinaki

22 August 2023 in Viruses
Verified
Journal Article
Open access
PDF file
EBEvangelos Thomas Bakaros
Evangelos Thomas Bakaros
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
VPVassiliki Paliatsa
Vassiliki Paliatsa
NGNikolaos K Gatselis
Nikolaos K Gatselis
GGGeorgios Germanidis
Georgios Germanidis
MSMatthaios Speletas
Matthaios Speletas
COVID-19 is characterized by a heterogeneous clinical presentation and prognosis. Risk factors contributing to the development of severe disease include old age and the presence of comorbidities. However, the genetic background of the host has also been recognized as an important determinant of disease prognosis. Considering the pivotal role of innate immunity in the control of SARS-CoV-2 infection, we analyzed the possible contribution of several innate immune gene polymorphisms (including TLR2-rs5743708, TLR4-rs4986790, TLR4-rs4986791, CD14-rs2569190, CARD8-rs1834481, IL18-rs2043211, and CD40-rs1883832) in disease severity and prognosis. A total of 249 individuals were enrolled and further divided into five (5) groups, according to the clinical progression scale provided by the World Health Organization (WHO) (asymptomatic, mild, moderate, severe, and critical). We identified that elderly patients with obesity and/or diabetes mellitus were more susceptible to developing pneumonia and respiratory distress syndrome after SARS-CoV-2 infection, while the IL18-rs1834481 polymorphism was an independent risk factor for developing pneumonia. Moreover, individuals carrying either the TLR2-rs5743708 or the TLR4-rs4986791 polymorphisms exhibited a 3.6- and 2.5-fold increased probability for developing pneumonia and a more severe disease, respectively. Our data support the notion that the host’s genetic background can significantly affect COVID-19 clinical phenotype, also suggesting that the IL18-rs1834481, TLR2-rs5743708, and TLR4-rs4986791 polymorphisms may be used as molecular predictors of COVID-19 clinical phenotype.

17 February 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MSMatthaios Speletas
Matthaios Speletas
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
Styliani SarrouStyliani Sarrou
Styliani Sarrou
KDKaterina Dadouli
Katerina Dadouli
Varvara MouchtouriVarvara Mouchtouri
Varvara Mouchtouri
Christos HadjichristodoulouChristos Hadjichristodoulou
Christos Hadjichristodoulou
The aim of our study was to investigate the immunogenicity of the BNT162b2 vaccination according to the age and medical status of vaccinated individuals. A total of 511 individuals were enrolled (median age: 54.0 years, range: 19–105); 509 of these individuals (99.6%) received two doses of BNT162b2 at an interval of 21 days. IgG and IgA responses were evaluated on days 21, 42, 90, and 180 after the first dose with chemiluminescent microparticle and ELISA assays. The cell-mediated immune responses were assessed by an automated interferon-gamma release assay. We demonstrated positive antibody responses after vaccination for the majority of enrolled participants, although waning of IgG and IgA titers was also observed over time. We further observed that the intensity of humoral responses was positively correlated with increased age and prior COVID-19 infection (either before or after the first vaccination). Moreover, we found that only a medical history of autoimmune disease could affect the intensity of IgA and IgG responses (3 weeks after the primary and secondary immunization, respectively), while development of systemic adverse reactions after the second vaccination dose was significantly associated with the height of IgG responses. Finally, we identified a clear correlation between humoral and cellular responses, suggesting that the study of cellular responses is not required as a routine laboratory test after vaccination. Our results provide useful information about the immunogenicity of COVID-19 vaccination with significant implications for public health vaccination strategies.

6 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Ioanna VoulgaridiIoanna Voulgaridi
Ioanna Voulgaridi
Styliani SarrouStyliani Sarrou
Styliani Sarrou
KDKaterina Dadouli
Katerina Dadouli
APAthanasia-Marina Peristeri
Athanasia-Marina Peristeri
ANAsimina Nasika
Asimina Nasika
Christos HadjichristodoulouChristos Hadjichristodoulou
Christos Hadjichristodoulou
The aim of the study was to compare mRNA vaccine BNT162b2 with adenovirus vector- based vaccines in terms of presence of adverse reactions, immunogenicity, and protection against COVID-19. A total of 270 individuals were enrolled, of which 135 were vaccinated with adenovirus vector-based vaccines and compared with 135 age- and sex-matched participants who received the BNT162b2 mRNA vaccine. Serum sampling was performed on all participants on days 21, 42, 90, and 180 following the first dose, to evaluate anti-spike IgG and IgA responses. Antibodies were quantified by chemiluminescent microplate and ELISA assays. We demonstrate that both mRNA and adenovirus vector-based vaccines caused mild side-effects and were effective in inducing adequate antibody responses against SARS-CoV-2, although BNT162b2 was superior concerning the intensity of antibody responses and protection against severe COVID-19. Moreover, we identify that IgG and IgA responses depended primarily on both history of previous COVID-19 infection and vaccination platform used, with individuals immunized with a single-dose vaccine having lower antibody titers over time. Lastly, all vaccine platforms had limited side-effects, with the most frequent pain at the injection site. Our results provide useful information regarding antibody responses after vaccination with different vaccine platforms, which can be useful for public health vaccination strategies.